Diagnostic efficacy of the nasal provocation test in patients with allergic rhinitis sensitive to house dust mites.

ational Center of Bioproducts (BioCen)0 sites300 target enrollmentApril 15, 2019

Overview

No summary available.

Registry

who.int

Start Date

April 15, 2019

End Date

December 7, 2022

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

ational Center of Bioproducts (BioCen)

•Allergic group (Group A):
•1\) Patients with a positive clinical history of persistent allergic rhinitis to home dust, according to the diagnostic criteria.
•2\) Age between 18 and 50 years.
•3\) Patients with a skin prick test with allergen extracts investigated (VALERGEN\-DP, VALERGEN\-DS and VALERGEN\-BT 20 000 UB/ mL), negative (diameter of wheal \<3 mm).
•4\) People of any sex who express their informed consent in writing to participate in the study.
•5\) Negative nasal discharge.
•6\) Physical Examination of anterior nostril negative for allergic rhinitis.
•\- Non\-allergic group (Group B):
•1\) Non\-allergic subjects without a positive clinical history of persistent allergic rhinitis to house dust, according to the diagnostic criteria described.
•2\) Age between 18 and 50 years.

•1\) Patients treated by Immunotherapy with allergenic extracts of D. pteronyssinus, D. siboney, D. farinae, B. tropical or home dust in the last two years.
•2\) Patients with symptoms of asthma, otitis media with effusion, acute sinusitis, rhinitis or conjunctivitis at the time of the tests.
•3\) Current use of drugs that interfere with the cutaneous and nasal reaction of the tests to be performed, which must be previously suspended.
•4\) Dermographism, atopic dermatitis in the area of skin test and urticaria.
•5\) Patients who do not express their written consent to participate in the study.